Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. by Vanderkerken, K, De Leenheer, E, Shipman, C, Asosingh, K, Willems, A, Van Camp, B, Croucher, P

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. by Shipman, C, Vanderkerken, K, Rogers, M, Lippitt, J, Asosingh, K, Hughes, D, Van Camp, B, Russell, R, Croucher, P

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma. by Croucher, P, Shipman, C, Perry, M, Lippitt, J, Asosingh, K, van Beek, E, Van Camp, B, Russell, G, Dunstan, C, Vanderkerken, K

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma by Croucher, P, Shipman, C, Perry, M, Lippitt, J, Asosingh, K, van Beek, E, Van Camp, B, Russell, R, Dunstan, C, Vanderkerken, K

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. by Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K